By healthBy-Health plans additional 70 million yuan investment in Moonshot AI, a related-party transaction approved by board, but flagged risks of high valuation and early-stage development.

By-Health plans to invest an additional 70 million yuan of its own funds in Moonshot AI Ltd. After this investment, the company and its subsidiaries will have a cumulative investment of approximately 175 million yuan in the target company. This additional investment constitutes a related-party transaction and has been approved by the board of directors, without the need for shareholder meeting approval. The announcement also flagged risks, noting that the target company operates in a sector with high valuations and is still in the early stages of development, facing potential risks such as technology research and development falling short of expectations and intense industry competition.
By healthBy-Health plans additional 70 million yuan investment in Moonshot AI, a related-party transaction approved by board, but flagged risks of high valuation and early-stage development.
Moonshot AI receives additional 70 million yuan investment from By-Health, indicating financial backing.